Neogen Chemicals · NSE: NEOGEN · BSE: 542665

Q4 FY22 results · Jan–Mar 2022

Neogen Chemicals reported revenue from operations of ₹156.80 crore (up 69.2% from Q4 FY21) and net profit of ₹15.64 crore (up 67.8% from Q4 FY21) for Q4 FY22 (Jan–Mar 2022), on a consolidated basis.

Consolidated · ₹ crore
ItemQ4 FY22Q4 FY21YoYQ3 FY22QoQ
Revenue from operations156.8092.70+69.2%132.64+18.2%
Other income0.850.0240x0.0328x
Total income157.6592.72+70.0%132.67+18.8%
Profit before share of associates & JVs and tax18.6613.18+41.6%13.76+35.6%
Share of profit/(loss) of associates & JVs0.080.06(0.01)
Net profit for the period15.649.32+67.8%10.46+49.5%
EPS, basic (₹)5.503.99+37.8%4.49+22.5%
Net margin (%)10.010.17.9

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
ItemQ4 FY22Q4 FY21YoYQ3 FY22QoQ
Revenue from operations156.8092.70+69.2%132.64+18.2%
Other income0.960.10+843.0%0.0424x
Total income157.7692.80+70.0%132.68+18.9%
Profit before tax18.7713.26+41.6%13.77+36.3%
Net profit for the period15.679.35+67.7%10.48+49.5%
EPS, basic (₹)5.504.00+37.5%4.50+22.2%
Net margin (%)10.010.17.9
Consolidated
Filed with BSE
19 May 2022, 17:28 IST
Board meeting
14 May 2022
Period
01 Jan 2022 to 31 Mar 2022
Review status
Audited
Source
XBRL filing on BSE
Standalone
Filed with BSE
19 May 2022, 17:28 IST
Board meeting
14 May 2022
Period
01 Jan 2022 to 31 Mar 2022
Review status
Audited
Source
XBRL filing on BSE